Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023 shares
Trading Arrangements, by Individual [Table]
Material Terms of Trading Arrangement	The information set forth below is included herein for the purpose of proving the disclosure required under “Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers”. (e) On November 7, 2023, the Company entered into an arrangement with Keith Kucinski, its chief financial officer and principal accounting officer, whereby it agreed to make incentive bonus payments in the amount of $40,000 on or before December 31, 2023, and $60,000 on April 1, 2024, to Mr. Kucinski if he is actively employed in good standing on each such date. If Mr. Kucinski resigns for any reason (other than for Good Reason) or if the Company terminates Mr. Kucinski for Cause (as such terms are defined in Mr. Kucinski’s employment agreement), within 60 days of such date, he is required to return the incentive bonus payment made to him on such date.
Name	Keith Kucinski
Title	chief financial officer and principal accounting officer
Adoption Date	November 7, 2023
Termination Date	December 31, 2023
Aggregate Available	40,000
Keith Kucinski [Member]
Trading Arrangements, by Individual [Table]
Termination Date	April 1, 2024
Aggregate Available	60,000